Safety and tolerability of antipsychotic-mood stabilizer co-treatment in the management of acute bipolar disorder: results from a systematic review and exploratory meta-analysis

Bibliography

• Grunze H, Kasper S, Goodwin G, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of bipolar disorders. Part I: Treatment of bipolar depression. World J Biol Psychiatry 2002;3(3):115-24
   PubMedGoogle Scholar
• Grunze H, Kasper S, Goodwin G, et al. The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders, Part II: Treatment of Mania. World J Biol Psychiatry 2003;4(1):5-13
   PubMed Web of Science ®Google Scholar
• Bipolar disorder: the assessment and management of bipolar disorder in adults, children and young people in primary and secondary care. NICE clinical guideline 185 [Internet]. 2014. Available from: http://www.nice.org.uk/guidance/cg185 [Cited 18 January 2015]
   Google Scholar
• Goodwin GM; Consensus Group of the British Association for Psychopharmacology. Evidence-based guidelines for treating bipolar disorder: revised second edition--recommendations from the British Association for Psychopharmacology. J Psychopharmacol Oxf Engl 2009;23(4):346-88
   PubMed Web of Science ®Google Scholar
• Yatham LN, Kennedy SH, Parikh SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. Bipolar Disord 2013;15(1):1-44
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry 2002;159(4 Suppl):1-50
   Web of Science ®Google Scholar
• Ogawa Y, Tajika A, Takeshima N, et al. Mood stabilizers and antipsychotics for acute mania: a systematic review and meta-analysis of combination/augmentation therapy versus monotherapy. CNS Drugs 2014;28(11):989-1003
   PubMed Web of Science ®Google Scholar
• Goldberg JF, Brooks JO, Kurita K, et al. Depressive illness burden associated with complex polypharmacy in patients with bipolar disorder: findings from the STEP-BD. J Clin Psychiatry 2009;70(2):155-62
   PubMed Web of Science ®Google Scholar
• Mojtabai R, Olfson M. National trends in psychotropic medication polypharmacy in office-based psychiatry. Arch Gen Psychiatry 2010;67(1):26-36
   PubMed Web of Science ®Google Scholar
• Forty L, Ulanova A, Jones L, et al. Comorbid medical illness in bipolar disorder. Br J Psychiatry 2014;205(6):465-72
   PubMed Web of Science ®Google Scholar
• Crump C, Sundquist K, Winkleby MA, Sundquist J. Comorbidities and mortality in bipolar disorder: a Swedish national cohort study. JAMA Psychiatry 2013;70(9):931-9
   PubMed Web of Science ®Google Scholar
• McElroy SL, Altshuler LL, Suppes T, et al. Axis I psychiatric comorbidity and its relationship to historical illness variables in 288 patients with bipolar disorder. Am J Psychiatry 2001;158(3):420-6
   PubMed Web of Science ®Google Scholar
• McIntyre RS, Konarski JZ, Yatham LN. Comorbidity in bipolar disorder: a framework for rational treatment selection. Hum Psychopharmacol 2004;19(6):369-86
   PubMed Web of Science ®Google Scholar
• Singh JB, Zarate CA. Pharmacological treatment of psychiatric comorbidity in bipolar disorder: a review of controlled trials. Bipolar Disord 2006;8(6):696-709
   PubMed Web of Science ®Google Scholar
• Baek JH, Ha K, Yatham LN, et al. Pattern of pharmacotherapy by episode types for patients with bipolar disorders and its concordance with treatment guidelines. J Clin Psychopharmacol 2014;34(5):577-87
   PubMed Web of Science ®Google Scholar
• Bowden CL. Making optimal use of combination pharmacotherapy in bipolar disorder. J Clin Psychiatry 2004;65(Suppl 15):21-4
   PubMedGoogle Scholar
• Smith LA, Cornelius V, Warnock A, et al. Acute bipolar mania: a systematic review and meta-analysis of co-therapy vs. monotherapy. Acta Psychiatr Scand 2007;115(1):12-20
   PubMed Web of Science ®Google Scholar
• Scherk H, Pajonk FG, Leucht S. Second-generation antipsychotic agents in the treatment of acute mania: a systematic review and meta-analysis of randomized controlled trials. Arch Gen Psychiatry 2007;64(4):442-55
   PubMed Web of Science ®Google Scholar
• Loebel A, Cucchiaro J, Silva R, et al. Lurasidone as adjunctive therapy with lithium or valproate for the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. Am J Psychiatry 2014;171(2):169-77
   PubMed Web of Science ®Google Scholar
• Sachs GS, Ice KS, Chappell PB, et al. Efficacy and safety of adjunctive oral ziprasidone for acute treatment of depression in patients with bipolar I disorder: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2011;72(10):1413-22
   PubMed Web of Science ®Google Scholar
• Sidor MM, Macqueen GM. Antidepressants for the acute treatment of bipolar depression: a systematic review and meta-analysis. J Clin Psychiatry 2011;72(2):156-67
   PubMed Web of Science ®Google Scholar
• Vázquez GH, Tondo L, Undurraga J, Baldessarini RJ. Overview of antidepressant treatment of bipolar depression. Int J Neuropsychopharmacol 2013;16(7):1673-85
   PubMed Web of Science ®Google Scholar
• Lucas RA, Gilfillan DJ, Bergstrom RF. A pharmacokinetic interaction between carbamazepine and olanzapine: observations on possible mechanism. Eur J Clin Pharmacol 1998;54(8):639-43
   PubMed Web of Science ®Google Scholar
• Skogh E, Reis M, Dahl M-L, et al. Therapeutic drug monitoring data on olanzapine and its N-demethyl metabolite in the naturalistic clinical setting. Ther Drug Monit 2002;24(4):518-26
   PubMed Web of Science ®Google Scholar
• Spina E, Pisani F, Perucca E. Clinically significant pharmacokinetic drug interactions with carbamazepine. An update. Clin Pharmacokinet 1996;31(3):198-214
   PubMed Web of Science ®Google Scholar
• DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7(3):177-88
   PubMedGoogle Scholar
• Sachs GS, Grossman F, Ghaemi SN, et al. Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double-blind, placebo-controlled comparison of efficacy and safety. Am J Psychiatry 2002;159(7):1146-54
   PubMed Web of Science ®Google Scholar
• Sachs GS, Vanderburg DG, Karayal ON, et al. Adjunctive oral ziprasidone in patients with acute mania treated with lithium or divalproex, part 1: results of a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2012;73(11):1412-19
   PubMed Web of Science ®Google Scholar
• Möller HJ, Kissling W, Riehl T, et al. Doubleblind evaluation of the antimanic properties of carbamazepine as a comedication to haloperidol. Prog Neuropsychopharmacol Biol Psychiatry 1989;13(1-2):127-36
   PubMed Web of Science ®Google Scholar
• Chou JC, Czobor P, Charles O, et al. Acute mania: haloperidol dose and augmentation with lithium or lorazepam. J Clin Psychopharmacol 1999;19(6):500-5
   PubMed Web of Science ®Google Scholar
• Berwaerts J, Lane R, Nuamah IF, et al. Paliperidone extended-release as adjunctive therapy to lithium or valproate in the treatment of acute mania: A randomized, placebo-controlled study. J Affect Disord 2011;129(1–3):252-60
   PubMed Web of Science ®Google Scholar
• Bourin MS, Severus E, Schronen JP, et al. Lithium as add-on to quetiapine XR in adult patients with acute mania: a 6-week, multicenter, double-blind, randomized, placebo-controlled study. Int J Bipolar Disord 2014;2:14
   PubMedGoogle Scholar
• Gao K, Wu R, Kemp DE, et al. Efficacy and Safety of Quetiapine-XR as Monotherapy or Adjunctive Therapy to a Mood Stabilizer in Acute Bipolar Depression With Generalized Anxiety Disorder and Other Comorbidities: A Randomized, Placebo-Controlled Trial. J Clin Psychiatry [ Internet 2014. Available from: http://www.psychiatrist.com/JCP/article/Pages/2014/aheadofprint/13m08847.aspx [Cited 2014 Oct 21]
   Google Scholar
• Houston JP, Tohen M, Degenhardt EK, et al. Olanzapine-divalproex combination versus divalproex monotherapy in the treatment of bipolar mixed episodes: a double-blind, placebo-controlled study. J Clin Psychiatry 2009;70(11):1540-7
   PubMed Web of Science ®Google Scholar
• Ravindran DA, Silverstone P, Lacroix D, et al. Risperidone does not affect steady-state pharmacokinetics of divalproex sodium in patients with bipolar disorder. Clin Pharmacokinet 2004;43(11):733-40
   PubMed Web of Science ®Google Scholar
• Sachs G, Chengappa K, Suppes T, et al. Quetiapine with lithium or divalproex for the treatment of bipolar mania: a randomized, double-blind, placebo-controlled study. Bipolar Disord 2004;6(3):213-23
   PubMed Web of Science ®Google Scholar
• Stedman M, Pettinati HM, Brown ES, et al. A double-blind, placebo-controlled study with quetiapine as adjunct therapy with lithium or divalproex in bipolar I patients with coexisting alcohol dependence. Alcohol Clin Exp Res 2010;34(10):1822-31
   PubMed Web of Science ®Google Scholar
• Szegedi A, Calabrese JR, Stet L, et al. Asenapine as adjunctive treatment for acute mania associated with bipolar disorder: results of a 12-week core study and 40-week extension. J Clin Psychopharmacol 2012;32(1):46-55
   PubMed Web of Science ®Google Scholar
• Tohen M, Chengappa KNR, Suppes T, et al. Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy. Arch Gen Psychiatry 2002;59(1):62-9
   PubMed Web of Science ®Google Scholar
• Tohen M, Bowden CL, Smulevich AB, et al. Olanzapine plus carbamazepine v. carbamazepine alone in treating manic episodes. Br J Psychiatry 2008;192(2):135-43
   PubMed Web of Science ®Google Scholar
• Van der Loos MLM, Mulder PGH, Hartong EGTM, et al. Efficacy and safety of lamotrigine as add-on treatment to lithium in bipolar depression: a multicenter, double-blind, placebo-controlled trial. J Clin Psychiatry 2009;70(2):223-31
   PubMed Web of Science ®Google Scholar
• Vieta E, Suppes T, Eggens I, et al. Efficacy and safety of quetiapine in combination with lithium or divalproex for maintenance of patients with bipolar I disorder (international trial 126). J Affect Disord 2008;109(3):251-63
   PubMed Web of Science ®Google Scholar
• Weisler RH, Dunn J, English P. Ziprasidone in adjunctive treatment of acute mania: a randomised, double-blind, placebo-controlled trial. Eur Neuropsychopharmacol 2003;13(Suppl 4):344-5
   Google Scholar
• Yatham LN, Grossman F, Augustyns I, et al. Mood stabilisers plus risperidone or placebo in the treatment of acute mania International, double-blind, randomised controlled trial. Br J Psychiatry 2003;182(2):141-7
   PubMed Web of Science ®Google Scholar
• Yatham LN, Vieta E, Young AH, et al. A double blind, randomized, placebo-controlled trial of quetiapine as an add-on therapy to lithium or divalproex for the treatment of bipolar mania. Int Clin Psychopharmacol 2007;22(4):212-20
   PubMed Web of Science ®Google Scholar
• Garfinkel PE, Stancer HC, Persad E. A comparison of haloperidol, lithium carbonate and their combination in the treatment of mania. J Affect Disord 1980;2(4):279-88
   PubMed Web of Science ®Google Scholar
• Vieta E, Valentí M. Pharmacological management of bipolar depression: acute treatment, maintenance, and prophylaxis. CNS Drugs 2013;27(7):515-29
   PubMed Web of Science ®Google Scholar
• Malhi GS, Bargh DM, McIntyre R, et al. Balanced efficacy, safety, and tolerability recommendations for the clinical management of bipolar disorder. Bipolar Disord 2012;14(Suppl 2):1-21
   PubMedGoogle Scholar
• Spina E, de Leon J. Metabolic drug interactions with newer antipsychotics: a comparative review. Basic Clin Pharmacol Toxicol 2007;100(1):4-22
   PubMed Web of Science ®Google Scholar
• Meltzer HY, Cucchiaro J, Silva R, et al. Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo- and olanzapine-controlled study. Am J Psychiatry 2011;168(9):957-67
   PubMed Web of Science ®Google Scholar
• Correll CU. Balancing efficacy and safety in treatment with antipsychotics. CNS Spectr 2007;12(10 Suppl 17):12-20; 35
   PubMed Web of Science ®Google Scholar
• Correll CU. From receptor pharmacology to improved outcomes: individualising the selection, dosing, and switching of antipsychotics. Eur Psychiatry 2010;25(Suppl 2):S12-21
   PubMed Web of Science ®Google Scholar
• De Hert M, Detraux J, van Winkel R, et al. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol 2012;8(2):114-26
   Web of Science ®Google Scholar